RxDoctor Payments Data

Christine Turner

Physician Assistant · Chatsworth, CANPI 1619011194

Payments from drug & device makers

$1,165in general payments, 2019–2025

Across 47 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$696
  • Dexcom, Inc.$180
  • Novo Nordisk$106
  • Lilly USA, LLC$102
  • Atricure, Inc.$48
  • Corcept Therapeutics$18
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$1,165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,165 in reported general payments places this provider in the 75th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$18,995
Medicare patients
50
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$70,432
JardianceEmpagliflozin29$20,359
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$14,132
Novolin NInsulin Nph Human Isophane17$5,194
Humulin NInsulin Nph Human Isophane22$3,918
Novolin RInsulin Regular, Human21$2,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,211
Nano 2nd Gen Pen NeedlePen Needle, Diabetic17$1,655
Humulin RInsulin Regular, Human20$1,455
Atorvastatin Calcium66$793
Gabapentin14$475
Metformin Hcl46$461
Benazepril Hcl29$391
Pioglitazone Hcl16$308
Losartan Potassium21$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$70,43282 claims
Lilly USA, LLCHumulin N$102$3,91822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Chatsworth

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →